| 產(chǎn)品名稱 |
SA13 |
| 商品貨號 |
B165659 |
| Organism |
human (B cell); human (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Peripheral blood B cells from a patient that had been immunized with tetanus toxoid were fused with LTR228 lymphoblastoid cells. |
| Clinical Data |
Peripheral blood B cells from a patient that had been immunized with tetanus toxoid were fused with LTR228 lymphoblastoid cells. |
| Cellular Products |
immunoglobulin; monoclonal antibody; against tetanus toxoid |
| Comments |
Peripheral blood B cells from a patient that had been immunized with tetanus toxoid were fused with LTR228 lymphoblastoid cells. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation |
Culture medium, 95%; DMSO, 5% |
| STR Profile |
Amelogenin: X,Y CSF1PO: 11,12 D13S317: 11,12 D16S539: 11,12 D5S818: 12,13 D7S820: 9,10,12 THO1: 8,10,9.3 TPOX: 8,10,11 vWA: 16,17,20 |
| Isotype |
IgG; kappa light chain |
| Antigenic Determinant |
Tetanus toxin |
| Name of Depositor |
Cetus Corp. |
| Deposited As |
human (B cell); human (myeloma) |
| U.S. Patent Number |
|
| References |
Raubitschek AR, et al. Human lymphoblastoid cell line and hybridomas derived therefrom. US Patent 4,624,921 dated Nov 25 1986
|
